Rheumatoid arthritis
Overview
•Symmetrical polyarthritis - MCP, PIP, and wrist joints most commonly; DIP joints typically spared
•Morning stiffness - lasting >1 hour, improves with activity (reflects active synovial inflammation)
•Systemic features - fatigue, malaise, low-grade fever
•Hand deformities (late disease) - ulnar deviation at MCPs, swan-neck (PIP hyperextension + DIP flexion), boutonnière (PIP flexion + DIP hyperextension), Z-deformity of thumb
RA vs OA - key distinguishing features
| Feature | Rheumatoid arthritis | Osteoarthritis |
|---|---|---|
| Morning stiffness | >1 hour, improves with activity | Few minutes, worsens with activity |
| Joints affected | MCP, PIP, wrist (DIP spared) | DIP, CMC, knee (MCP/PIP less common) |
| Distribution | Symmetrical polyarthritis | Asymmetrical, weight-bearing joints |
| X-ray: specific findings | Periarticular erosions, juxta-articular osteoporosis, soft tissue swelling | Osteophytes, subchondral sclerosis, subchondral cysts |
| Hand sign | Swan-neck, boutonnière, ulnar deviation | Squaring of thumb (CMC subluxation) |
Investigations
•Anti-CCP antibodies - positive in ~80% RA; specificity ~96%; most diagnostically useful serological test
•Rheumatoid factor (RF) - positive in 60-70% RA; low specificity (positive in infection, other autoimmune diseases)
•CRP and ESR - raised; correlate with disease activity
•X-rays of hands and feet - four characteristic findings: periarticular erosions (most specific/diagnostically supportive), juxta-articular osteoporosis (earliest finding), soft tissue swelling, joint space narrowing
•U&Es and LFTs - baseline before DMARDs (methotrexate is hepatotoxic; NSAIDs are nephrotoxic)
Management
•Treat-to-target - aim for DAS28 remission (<2.6) or low disease activity (<3.2); reassess monthly in active disease
•First-line DMARD: methotrexate - initiate ideally within 3 months of symptom onset; early treatment reduces structural damage
•Bridge therapy: NSAIDs (with PPI cover) or short-course corticosteroids while awaiting DMARD effect
•Non-pharmacological - physiotherapy, occupational therapy, podiatry, psychological support
•Annual cardiovascular risk assessment - aggressive risk factor management; IHD is the leading cause of premature death
Extra-articular features
•Cardiovascular - accelerated atherosclerosis; ischaemic heart disease is the leading cause of excess mortality in RA (approximately double the risk of the general population)
•Respiratory - pulmonary fibrosis (lower zone), pleural effusions, pulmonary nodules
•Rheumatoid nodules - firm, subcutaneous, at pressure points (e.g. olecranon); seropositive patients only
•Felty syndrome - RA + splenomegaly + neutropenia; increased infection risk
•Ophthalmic - keratoconjunctivitis sicca, episcleritis, scleritis
•Atlanto-axial subluxation - cervical myelopathy in severe longstanding disease